Information  X 
Enter a valid email address

Tiziana Life Sci PLC (TILS)

  Print      Mail a friend

Monday 20 November, 2017

Tiziana Life Sci PLC

Subscription

RNS Number : 9022W
Tiziana Life Sciences PLC
20 November 2017
 

Tiziana Life Sciences plc

("Tiziana" or the "Company")

 

Subscription to raise £150,000 with warrants attached

 

London, November 20, 2017 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces that it has raised £150,000 in cash by the issue of 100,000 new ordinary shares at a price of 150p per share, each new ordinary share having a warrant attached entitling the holder to subscribe for one new ordinary share at a price of 160p per share, exercisable until 24 November 2022.

 

Application has been made to the London Stock Exchange to admit the 100,000 new ordinary shares to trading on AIM.  Admission of the new ordinary shares is expected to occur on or around 24 November 2017.  The new ordinary shares will rank pari passu with the existing ordinary shares. Following the issue of shares detailed above the so enlarged issued share capital of the Company will comprise 123,927,938 ordinary shares of 3p each.

 

The Company has granted options over a total of 10,149,403 ordinary shares of which 4,752,500 are vested at exercise prices between 15p and £1.25p per share and 5,396,903 remain subject to vesting conditions (at potential exercise prices ranging from 15p to £1.925 per share). In addition warrants to subscribe for a total of 4,239,579 ordinary shares at exercise prices between 50p and £2.50 are outstanding, in additional to the new warrants granted in the fundraise.

 

Therefore the fully diluted issued share capital of the Company is 138,416,920 ordinary shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).

 

In conformity with DTR 5.6.1 the Company notifies that as at the date of this announcement, it has a single class of shares in issue being ordinary shares of 3 pence each ("Ordinary Shares") and that following the issue of the 100,000 ordinary shares referred to above, the total number of Ordinary Shares in issue will be 123,927,938.  There are no Ordinary Shares held in Treasury.  Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

 

This figure (123,927,938) may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Contacts

 

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

 

+44 (0)20 7493 2853

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner

 

+44 (0)20 7213 0880

Beaufort Securities Limited (Broker)

Saif Janjua

 

+44 (0)20 7382 8300

FTI Consulting

Simon Conway / Natalie Garland-Collins

+44 (0)20 3727 1000

 

About Tiziana Life Sciences

 

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

For more information go to http://www.tizianalifesciences.com 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCOKCDKDBDDQDD

a d v e r t i s e m e n t